Lung Cancer

Clinical trials for patients with cancer in the tissue of one or both lungs.

If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit the Joining a Clinical Trial page for referral information. 

For more information on clinical trials, get in contact with our cancer clinical trials enquiry coordinator.

Clinical Trials Enquiry Coordinator

Business hours, Mon to Friday between 9am - 2pm
Email [email protected]
Phone (03) 8559 7456

Open and Recruiting Clinical Trials

A clinical trial to test the safety and effectiveness of the treatment Alectinib compared to chemotherapy in patients with non-small cell lung cancer

Cancer type

Non-small cell lung cancer

Status

Open and recruiting

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.

Brief summary

The aim of the clinical trial is to test if the treatment Alectinib is better at treating a type of non-small cell lung cancer called anaplastic lymphoma kinase positive (or ALK positive) compared to approved chemotherapy treatments used to treat this type of cancer. ALK positive changes can cause lung cells to grow abnormally which can lead to cancer. The treatment Alectinib works by targeting the ALK positive cells with the potential to stop or reverse cancer growth.

Patients on clinical trial will receive either of the following:

Arm 1: Alectinib

Arm 2: Chemotherapy

Who can participate

Patients who:

  • Have had their cancer surgically removed
  • Have ALK positive cancer

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test if early referral to palliative care services can improve the quality of life and health of patients with lung cancer or mesothelioma

Cancer type

Lung cancer or mesothelioma

Status

Open and recruiting

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.

Brief summary

The aim of this clinical trial is to test if early referral to access palliative care services soon after diagnosis with advanced lung cancer or mesothelioma can improve the quality of life for patients. Palliative care is care that helps patients live their life as fully and as comfortably as possible when living with a life-limiting illness. Palliative care identifies and treats symptoms which may be physical, emotional, spiritual or social. Because palliative care is based on individual needs, the services offered will differ for each patient.

Who can participate

Patients who:

  • Have advanced cancer

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test the safety and effectiveness of a new treatment Repotrectinib in patients with certain types of lung cancer

Cancer type

Lung cancer with certain changes in the genes of the cancer (ROS1, NTRK1, NTRK2, or NTRK3)

Status

Open and recruiting

Phase

One/two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer.

Brief summary

Tyrosine kinases (TKs) are a group of proteins in the body that control the growth of cells. ROS1, NTRK1, NTRK2, and NTRK3 are genes that tell the body to make certain TKs. Changes in the ROS1, NTRK1, NTRK2, or NTRK3 genes can cause too many TKs to be made, or cause TKs to be overactive. This can cause cells to grow out of control and cancer can develop. The treatment Repotrectinib works by stopping the changes in the ROS1, NTRK1, NTRK2, and NTRK3 genes. The aim of the clinical trial is to test if Repotrectinib can stop cells growing out of control and therefore help treat the cancer. All patient in this study will receive Repotrectinib

Who can participate

Patients who:

  • Have ROS1, NTRK1, NTRK2, or NTRK3 changes in the genes of the cancer
  • Have cancer that has grown outside the body part it started in but has not yet spread to other parts of the body OR
  • Cancer that has spread to other parts of the body

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test if the treatment Selpercatinib given with Pemetrexed and with or without Pembrolizumab is better than chemotherapy as a first treatment for patients with a certain type of lung cancer

Cancer type

Non-squamous non-small cell lung cancer

Status

Open and recruiting

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.

Brief summary

The aim of the clinical trial is to test if the treatment Selpercatinib in combination with Pemetrexed therapy, with or without Pembrolizumab is better than platinum-based chemotherapy (Carboplatin or Cisplatin) in the treatment of patients with Non-squamous non-small cell lung cancer. Selpercatinib is a type of treatment that works by stopping a gene in the cancer called RET. RET is a gene involved in the normal development of cells. If the RET gene changes, it can cause similar changes in growing cells, which can lead to cancer. By stopping the RET gene, Selpercatinib may stop, slow, or reverse the growth of cancer cells.

Who can participate

Patients who:

  • Have changes in RET genes (RET fusion-positive)
  • Are not suitable for surgery or radiotherapy

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test the idea that changing between two different treatments can improve the chances of treatment working of patients with a type of non-small cell lung cancer called anaplastic lymphoma kinase positive (or ALK positive)

Cancer Type

ALK positive non-small cell lung cancer

Status

Opening soon

Phase

Proof of concept: a proof of concept clinical trial is a certain way or idea being tested to see if it is useful, and can be applied in patient care. 

Brief summary

The aim of the clinical trial is to test if changing between the two treatments Lorlatinib and Crizotinib, can lengthen the time the treatments are effective and to test if dosing the treatments in this way is safe. Patients with a type of non-small cell lung cancer called anaplastic lymphoma kinase positive (or ALK positive) are suitable for this clinical trial. ALK positive changes can cause lung cells to grow abnormally which can lead to cancer. Targeting the ALK positive gene can help the growth rate of the cancer.

Who can participate

Patients who:

  • Have had treatment for their cancer but it has become worse or has not responded to treatment
  • Are ALK positive

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test if the treatment AMG 510 is more effective than Docetaxel in patients with lung cancer

Cancer Type

Lung cancer with specific changes in the genes of the cancer (KRAS G12C)

Status

Open and recruiting

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type

Brief summary

This clinical trial compares the safety and effectiveness of new treatment AMG 510 to a type of chemotherapy, Docetaxel in patients with that has spread to other parts of the body and have KRAS G12C changes in the genes of their cancer. KRAS G12C changes can increase the growth of lung cancer. The treatment AMG 510 works by targeting KRAS G12C changes and stopping the cancer cell growth.

Who can participate

Patients who:

  • Have lung cancer with specific changes in the genes of the cancer (KRAS G12C)
  • Have cancer that has spread to other parts of the body
  • Have had treatment for their cancer but it has gotten worse or have not responded to treatment given for their lung cancer

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to find the best dose and test the safety and effectiveness of the new treatment DZD9008 in patients with non-small cell lung cancer with EGFR or HER2 changes in the genes of the cancer

Cancer type

Non-small cell lung cancer with EGFR or HER2 changes in the genes of the cancer

Status

Opening Soon

Phase

One/two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer.

Brief summary

DZD9008 is an oral drug which works by stopping certain changes in the genes of the cancer which control cancer growth. The clinical trial has two parts:

Part 1: To find the best and safest dose of DZD9008

Part 2: To test the safety and effectiveness on the different non-small cell lung cancer types (EGFR and HER2)

The aim of the clinical trial is to test if the treatment can shrink the cancer or stop the cancer from growing.

Who can participate

Patients who:

  • Have EGFR or HER2 changes in the genes of the cancer
  • Have had treatment for their cancer but it has gotten worse or have not responded to treatment given for their cancer
  • Are able to swallow medication by mouth

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test the safety and effectiveness of the treatment Durvalumab in combination with available chemotherapy for patients with mesothelioma lung cancer

Cancer type

Mesothelioma lung cancer

Status

Opening soon

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.

Brief summary

The aim of this clinical trial is to test the effectiveness of the treatment Durvalumab given in combination with the available chemotherapy regiment (Cisplatin and Pemetrexed) in patients with mesothelioma lung cancer.

Durvalumab is a type of treatment called immunotherapy which work with the body’s immune system to fight the cancer. Patients on clinical trial will receive either of the following:

Arm 1: Durvalumab given with chemotherapy (Cisplatin and Pemetrexed) every 3 weeks for 4 to 6 cycles, followed by Durvalumab given alone every 4 weeks

Arm 2: Chemotherapy (Cisplatin and Pemetrexed) every 3 weeks for 4 to 6 cycles

Who can participate

Patients who:

  • Have had treatment for their cancer but it has gotten worse or have not responded to treatment given for their cancer
  • Unable to have curative surgical resection

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test the safety and effectiveness of giving the treatment Durvalumab with chemotherapy in patients with non-small-cell lung cancer who have had their cancer removed surgically.

Cancer type

Non-small cell lung cancer

Status

Opening Soon

Phase

Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.

Brief summary

The clinical trial aims to find out whether patients who have had their lung cancer surgically removed are less likely to have their cancer come back if they are given the treatment Durvalumab, (a treatment that helps the immune system to attack the cancer) with chemotherapy. Durvalumab will be given with chemotherapy a standard treatment option for patients post-surgery. Half the patients will be given chemotherapy, the other half will be given Durvalumab and chemotherapy. Neither the patients nor the researchers will know which patients are getting Durvalumab.

Who can participate

Patients who:

  • Will be treated or have already been treated by surgery to remove the cancer

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.

A clinical trial to test the safety and effectiveness of the new treatment U3-1402 in patients with non-small-cell lung cancer who have previously been treated with chemotherapy and tyrosine kinase inhibitors

Cancer type

Non-small cell lung cancer

Status

Opening Soon

Phase

Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.

Brief summary

A clinical trial to test whether the new treatment U3-1402 is effective in patients with non-small cell lung cancer who have progressed after being treated with chemotherapy and a type of cancer treatment called a tyrosine kinase inhibitor which targets specific changes in the genes of the cancer. The clinical trial will test if U3-1402 can shrink the cancer or stop it from growing.

Who can participate

Patients who:

  • Have specific changes in the genes of the cancer (EGFR)
  • Have had treatment for their cancer but it has gotten worse or has not responded to treatment.

Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.